An experimental radioactive contrasting agent for use in medical scans that could allow doctors to tailor treatment for cancer patients by tracking the growth pattern of new blood vessels feeding tumors is being tested by GE Healthcare.
An experimental radioactive contrasting agent for use in medical scans that could allow doctors to tailor treatment for cancer patients by tracking the growth pattern of new blood vessels feeding tumors is being tested by GE Healthcare.